Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Current work and future possibilities for the management of severe influenza: Using immunomodulatory agents that target the host response

dc.contributor.authorAlleva, Lisa
dc.contributor.authorGualano, Rosa C
dc.contributor.authorClark, Ian A
dc.date.accessioned2015-12-10T23:36:37Z
dc.date.issued2011
dc.date.updated2016-02-24T08:23:58Z
dc.description.abstractIn this article, we argue the case that the excessive inflammatory response seen in severe influenza contributes to severe illness and death by disabling oxidative phosphorylation in mitochondria, leading to reduced cellular levels of ATP. When the mitochondrial permeability transition is induced, cells cannot die by apoptosis in the face of reduced ATP levels, because apoptosis depends upon ATP availability, and so cells undergo necrosis. Cellular necrosis causes release of proinflammatory molecules such as high mobility group box 1 protein and mitochondrial DNA, and these could contribute to the prolongation of inflammation during severe influenza. With these concepts in mind, we discuss how immunomodulatory agents that prevent cellular necrosis (by restoring mitochondrial function) and limit inflammation are promising influenza treatments.
dc.identifier.issn1746-0794
dc.identifier.urihttp://hdl.handle.net/1885/70216
dc.publisherFuture Science Group
dc.sourceFuture Virology
dc.subjectKeywords: adenosine triphosphate; flavonoid; gemfibrozil; glycyrrhizic acid; high mobility group B1 protein; immunomodulating agent; mitochondrial DNA; phytoestrogen; pioglitazone; plant extract; polyphenol; resveratrol; rosiglitazone; simvastatin; telmisartan; 200 complementary and alternative medicine; fibrate; glitazone; glycyrrhizin; H1N1 pandemic; H5N1; HMGB1; inflammation; influenza; mitochondria; statin
dc.titleCurrent work and future possibilities for the management of severe influenza: Using immunomodulatory agents that target the host response
dc.typeJournal article
local.bibliographicCitation.issue7
local.bibliographicCitation.lastpage854
local.bibliographicCitation.startpage843
local.contributor.affiliationAlleva, Lisa, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationGualano, Rosa C, University of Melbourne
local.contributor.affiliationClark, Ian A, College of Medicine, Biology and Environment, ANU
local.contributor.authoruidAlleva, Lisa, u9306857
local.contributor.authoruidClark, Ian A, a261318
local.description.embargo2037-12-31
local.description.notesImported from ARIES
local.identifier.absfor110309 - Infectious Diseases
local.identifier.absseo920109 - Infectious Diseases
local.identifier.ariespublicationf2965xPUB2255
local.identifier.citationvolume6
local.identifier.doi10.2217/fvl.11.51
local.identifier.scopusID2-s2.0-79960413119
local.type.statusPublished Version

Downloads

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
01_Alleva_Current_work_and_future_2011.pdf
Size:
959.71 KB
Format:
Adobe Portable Document Format
abcd